S'abonner

Best practices for reducing pain associated with intrauterine device placement - 08/05/25

Doi : 10.1016/j.ajog.2025.01.039 
Lisa L. Bayer, MD, MPH, FACOG a, , Samir Ahuja, MD, FACOG b, Rebecca H. Allen, MD, MPH, FACOG c, Melanie A. Gold, DO, DMQ, DABMA, FAAP d, Jeffrey P. Levine, MD, MPH e, Lynn L. Ngo, MD, MPH, FACOG f, Sheila Mody, MD, MPH, FACOG g
a Division of Complex Family Planning, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR 
b Department of Obstetrics & Gynecology, University Hospitals, Cleveland, OH 
c Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, RI 
d Special Lecturer, Department of Pediatrics and Department of Population & Family Health, Columbia University Irving Medical Center, New York, NY 
e Professor and Director of Reproductive & Gender Health Programs, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 
f Department of Obstetrics and Gynecology, Southern California Permanente Medical Group, San Diego, CA 
g Director, Division & Fellowship Complex Family Planning, Department of Obstetrics, Gynecology & Reproductive Services, UC San Diego, CA 

Corresponding author: Lisa Bayer, MD, MPH.

Abstract

Intrauterine devices are highly effective, long-acting, reversible forms of contraception. Despite their benefits, limited uptake persists, particularly among underserved populations, adolescents, and young adults. While most intrauterine device placement procedures are uncomplicated, pain is commonly reported, with more severe pain reported in certain groups. No current standard of care has been established specifically to manage pain with intrauterine device placement, resulting in wide variation in clinical practice. This article aims to provide practical, evidence-based, and expert-informed guidelines for managing pain during intrauterine device placement. The authors (a group of board-certified obstetrician-gynecologists, pediatricians, and a family physician) conducted a virtual expert meeting to develop consensus-based recommendations for pain management. The meeting covered environmental considerations, nonpharmacological, and pharmacological options. Key strategies include using a person-centered care model that focuses on patient values, needs, and preferences to promote shared decision-making around pain relief. Clinicians should assist patients in setting realistic expectations, including a discussion of the placement procedure, anticipated pain, and all options for pain relief, to allow for a comprehensive informed consent process. Nonpharmacological interventions, such as the use of therapeutic language and comforting environmental, complementary and integrative, and mind-body elements, are recommended to reduce patient anxiety and discomfort. In terms of pharmacological options, clinicians may offer pre-procedural–specific nonsteroidal antiinflammatory drugs (eg, naproxen and ketorolac) and anxiolytics to patients with significant anxiety, as well as intraprocedural application of topical anesthesia and paracervical or intracervical blocks. Finally, additional techniques, such as using appropriately sized instruments and ensuring gradual and gentle procedural steps, can also help enhance patient comfort during insertion. These expert guidelines emphasize the importance of personalized, trauma-informed, and evidence-based care, prioritizing patient autonomy and preferences to facilitate a safe and acceptable insertion experience. They are critical to reducing barriers to intrauterine device uptake and improving overall patient outcomes.

Le texte complet de cet article est disponible en PDF.

Key words : analgesia, anxiety/prevention & control, contraception, integrative medicine (preferred MeSH term), intrauterine device (IUD), pain/prevention & control, paracervical block


Plan


 All authors participated in a virtual advisory board meeting supported by Bayer. Following the advisory board, the authors developed the concepts and manuscript. The authors were not paid for their participation in the writing process. Melanie Gold: Consultant presenting on Patient Centered Contraceptive Counseling (not product-specific; current): Bayer. Research funding on Telehealth-Supported Long-Acting Reversible Contraception in School Based Health Centers (ended 2023): Merck/Organon. Consultant on expert panel on Scientific Workshop on Shared Decision Making (ended 2023): Glaxo Smith Kline (GSK). Research Consultant for Policy and Research Group: Current. Research Consultant for 5 Point App: Current. Consultant for The Tapping Solution, LLC and The Tapping Solution Foundation: (Ended August 31, 2024). Rebecca Allen attended a Bayer Advisory Board for a new IUD inserter (2024). The remaining authors report no conflict of interest.
 A virtual advisory board meeting was held on March 7, 2024, supported by Bayer, who also funded medical writing and editorial support.


© 2025  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 232 - N° 5

P. 409-421 - mai 2025 Retour au numéro
Article précédent Article précédent
  • AJOG GR Table of Contents
| Article suivant Article suivant
  • Vaginal antiseptic preparation at the time of hysterectomy: a systematic review and meta-analysis
  • Sarah K. Rozycki, Vylan Nguyen, Natalia Miroballi, Emily C. Rutledge, Ethan M. Balk, Danielle D. Antosh

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.